Report cover image

Global Prostate Cancer PARP Inhibitor Drugs Market Growth 2025-2031

Publisher LP Information, Inc.
Published Nov 18, 2025
Length 101 Pages
SKU # LPI20579548

Description

The global Prostate Cancer PARP Inhibitor Drugs market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.

Poly ADP-ribose polymerase (PARP) is a DNA repair enzyme involved in the single-strand repair process of DNA. PARP inhibitors (PARPi) inhibit PARP activity through two mechanisms: direct inhibition of PARP function and PARP trapping, resulting in the stalling and collapse of replication forks, resulting in fatal double-strand breaks. Normal cells can repair double-strand breaks in time and correctly through homologous recombination repair (HRR); however, in tumor cells carrying HRR gene mutations, due to the impairment or loss of HRR function, the accumulated double-strand breaks will not be repaired in time and correctly, resulting in The tumor cell genome is unstable and eventually induces tumor cell death.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

LP Information, Inc. (LPI) ' newest research report, the “Prostate Cancer PARP Inhibitor Drugs Industry Forecast” looks at past sales and reviews total world Prostate Cancer PARP Inhibitor Drugs sales in 2024, providing a comprehensive analysis by region and market sector of projected Prostate Cancer PARP Inhibitor Drugs sales for 2025 through 2031. With Prostate Cancer PARP Inhibitor Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Prostate Cancer PARP Inhibitor Drugs industry.

This Insight Report provides a comprehensive analysis of the global Prostate Cancer PARP Inhibitor Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Prostate Cancer PARP Inhibitor Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Prostate Cancer PARP Inhibitor Drugs market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Prostate Cancer PARP Inhibitor Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Prostate Cancer PARP Inhibitor Drugs.

This report presents a comprehensive overview, market shares, and growth opportunities of Prostate Cancer PARP Inhibitor Drugs market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
Lynparza
Zejula
Talzenna
Fluzoparib
PamiPali
Other

Segmentation by Application:
Hospital
Specialty Clinic
other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
AstraZeneca
Merck & Co., Inc
GSK
Pfizer
Johnson & Johnson
Takeda Pharmaceutical Company Limited
BeiGene, Inc
Jiangsu Hengrui Pharmaceuticals Co., Ltd

Key Questions Addressed in this Report

What is the 10-year outlook for the global Prostate Cancer PARP Inhibitor Drugs market?

What factors are driving Prostate Cancer PARP Inhibitor Drugs market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Prostate Cancer PARP Inhibitor Drugs market opportunities vary by end market size?

How does Prostate Cancer PARP Inhibitor Drugs break out by Type, by Application?

Please note: The report will take approximately 2 business days to prepare and deliver.

Table of Contents

101 Pages
*This is a tentative TOC and the final deliverable is subject to change.*
1 Scope of the Report
2 Executive Summary
3 Global by Company
4 World Historic Review for Prostate Cancer PARP Inhibitor Drugs by Geographic Region
5 Americas
6 APAC
7 Europe
8 Middle East & Africa
9 Market Drivers, Challenges and Trends
10 Manufacturing Cost Structure Analysis
11 Marketing, Distributors and Customer
12 World Forecast Review for Prostate Cancer PARP Inhibitor Drugs by Geographic Region
13 Key Players Analysis
14 Research Findings and Conclusion

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us